FADS1 and colorectal carcinoma: Furthermore, we found that 8 out of 10 interacting proteins interacted with known CRC drug targets (Figure 8D and Table S30), further supporting the therapeutic relevance of this network and the potential for targeted intervention strategies centered on FADS1-associated pathways.